Frédèric Selle
Impact in
- Reproductive Medicine top 0.1%
- Ovarian cancer diagnosis and treatment
- Oncology top 0.5%
- PARP inhibition in cancer therapy
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Ovarian cancer diagnosis and treatment 91
- Oncology 52
- PARP inhibition in cancer therapy 36
- Pancreatic and Hepatic Oncology Research 4
- Cancer Treatment and Pharmacology 3
- Co-authors
- Thierry André (7 shared papers)Christophe Louvet (6 shared papers)Aimery de Gramont (4 shared papers)Jean‐Pierre Lotz (21 shared papers)Roman Rouzier (18 shared papers)Émile Daraï (14 shared papers)Elisabeth Chereau (13 shared papers)Pascal R. Hammel (3 shared papers)
In The Last Decade
Frédèric Selle
147 papers receiving 9.3k citations
Frédèric Selle's Hit Papers
Peers
Comparison fields: 5 of 103
- Reproductive Medicine 3.7k
- Oncology 3.7k
- Obstetrics and Gynecology 581
- Cancer Research 286
- Genetics 595
Countries citing papers authored by Frédèric Selle
This map shows the geographic impact of Frédèric Selle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédèric Selle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédèric Selle more than expected).
Fields of papers citing papers by Frédèric Selle
This network shows the impact of papers produced by Frédèric Selle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédèric Selle. The network helps show where Frédèric Selle may publish in the future.
Co-authors
The 25 scholars most cited alongside Frédèric Selle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 158 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | A Phase 3 Trial of Bevacizumab in Ovarian Cancer Hit paper breakdown → | 2011 | 1747 |
| 2 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 1574 |
| 3 | Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer Hit paper breakdown → | 2019 | 1527 |
| 4 | 2007 | 422 | |
| 5 | 2004 | 329 | |
| 6 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2021 | 326 |
| 7 | Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial Hit paper breakdown → | 2023 | 231 |
| 8 | Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer Hit paper breakdown → | 2021 | 213 |
| 9 | 2006 | 202 | |
| 10 | 2015 | 191 | |
| 11 | 2018 | 161 | |
| 12 | Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2023 | 150 |
| 13 | 2021 | 117 | |
| 14 | 2012 | 101 | |
| 15 | 2021 | 100 | |
| 16 | 2015 | 98 | |
| 17 | 2016 | 88 | |
| 18 | 2010 | 86 | |
| 19 | 2010 | 78 | |
| 20 | 2023 | 75 |
About Frédèric Selle
Frédèric Selle is a scholar working on Reproductive Medicine, Oncology, Obstetrics and Gynecology, Surgery and Pulmonary and Respiratory Medicine, having authored 158 papers that have together received 9.6k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (91 papers), PARP inhibition in cancer therapy (36 papers), Endometrial and Cervical Cancer Treatments (9 papers), Testicular diseases and treatments (6 papers), Sarcoma Diagnosis and Treatment (4 papers), Pancreatic and Hepatic Oncology Research (4 papers), Cancer Treatment and Pharmacology (3 papers) and Uterine Myomas and Treatments (3 papers). The work is most often cited by research in Reproductive Medicine (3.7k citations), Oncology (3.7k citations), Obstetrics and Gynecology (581 citations), Cancer Research (286 citations) and Genetics (595 citations). Frédèric Selle has collaborated with scholars based in France, Germany and Spain. Frequent co-authors include Thierry André, Christophe Louvet, Aimery de Gramont, Jean‐Pierre Lotz, Roman Rouzier, Émile Daraï, Elisabeth Chereau, Pascal R. Hammel, Jacques Balosso and Philippe B Ruszniewski. Their work appears in journals such as Annals of Oncology, International Journal of Gynecological Cancer, Gynecologic Oncology, Journal of Clinical Oncology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.